| Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors |
13 |
| Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta |
7 |
| Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic |
6 |
| Treatment as Prevention for HIV Infection: Current Data, Challenges, and Global Perspectives |
5 |
| HTLV-1 Associated Neurological Complex. What is Hidden below the Water? |
4 |
| Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS |
4 |
| Is UNAIDS 90-90-90 target a Dream or a Reality for Middle East and North Africa Region on Ending the AIDS Epidemic? A Review Study |
4 |
| State of the Antiretroviral Therapy in Human Immunodeficiency Virus Drug Resistance: Science and Technology Knowledge Gap |
4 |
| Prevalence of Tuberculosis in HIV-positive Prisoners: A Systematic Review and Meta-analysis |
3 |
| Differential Contribution of HIV-1 Subtypes B and C to Neurological Disorders: Mechanisms and Possible Treatments |
3 |
| HIV-1 and Compromised Adult Neurogenesis: Emerging Evidence for a New Paradigm of HAND Persistence |
3 |
| Evolution of Interdisciplinary Landscapes of HIV/AIDS Studies from 1983 to 2017: Results from the Global Analysis for Policy in Research (GAP(RESEARCH)) |
3 |
| Chronic Lung Disease in HIV Patients |
3 |
| Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis |
2 |
| The Use of Health Behavioral Theories in HIV/AIDS Research: A Bibliometric Analysis (Gap Research) |
2 |
| Economic Impact of HIV in the Highly Active Antiretroviral Therapy Era - Reflections Looking Forward |
2 |
| Report from the International Conference on Viral Hepatitis-2017 |
2 |
| Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen? |
1 |
| Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect |
1 |
| Conceptual Framework for Investigating and Influencing Adherence Behavior among HIV-Positive Populations: An Applied Social Cognition Model |
1 |
| HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic |
1 |
| The Role of HIV in the Progression through the Stages of the Human Papillomavirus to Cervica Cancer Pathway |
1 |
| HIV Treatment Adherence - A Shared Burden for Patients, Health-Care Providers, and Other Stakeholders |
1 |
| The Safety and Efficacy of Marijuana in Persons Living with HIV |
1 |
| New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy |
1 |
| Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed |
1 |
| Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence |
1 |
| Tolerability of Current Antiretroviral Single-Tablet Regimens |
1 |
| Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection |
1 |
| Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review |
1 |
| The Role of the Clinical Pharmacist in the Management of People Living with HIV in the Modern Antiretroviral Era |
1 |
| Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned |
0 |
| Quantification of Hepatitis B Surface Antigen: Is there a Role in HIV-Hepatitis B Virus Coinfection? |
0 |
| Malignant Melanoma in People Living with HIV/AIDS: Can We Know More, Can We Do Better? |
0 |
| A Model for Potential B-cell Precursors of Broadly Neutralizing HIV-1 Antibodies Selection and Antibody Affinity Maturation |
0 |
| State of the Antiretroviral Therapy in Human Immunodeficiency Virus Drug Resistance: Surveillance and Regional Gaps |
0 |
| Moving Fourth: A Vision Toward Achieving Healthy Living with HIV Beyond Viral Suppression |
0 |
| Is Antiretroviral Two-Drug Regimen the New Standard for HIV Treatment in Naive Patients? |
0 |
| Viral Inhibitory Activity of CD8+T Cells in HIV Infection |
0 |
| A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice |
0 |
